Identity provider (SAML)

City of Hope and TGen Research Reveals What Potentially Causes a Leukemia to Become More Aggressive

Retrieved on: 
Wednesday, October 11, 2023
Research, Genetics, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Mining, Multimedia, HIV disease progression rates, Food, Division, Food and Drug Administration Amendments Act of 2007, Genome, RNA, CML, Identity provider (SAML), Carter, Heart, AML, Disease, Patient, City, Leukemia Research, City of Hope, Acute leukemia, Bone marrow, Gene, Ruxolitinib, Robert, Clinical trial, Myeloproliferative neoplasm, Mouse, Translational Genomics Research Institute, Pancreatic serous cystadenoma, Nature Communications, BP, SAML, Pharmaceutical industry, Vaccine, Medical imaging, Hope, Leukemia

View the full release here: https://www.businesswire.com/news/home/20231011243325/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231011243325/en/
    City of Hope's Guido Marcucci, M.D., and team conducted the research.
  • They found that adding miR-142 prevented CML transformation and some mice with BP CML were even cured of their disease.
  • Another track funds a diagnostic project at TGen using genomic sequencing to uncover strategies to pinpoint and prevent disease progression.
  • Thanks to the Carter Altman Foundation, the TGen team is viewing all 3 billion letters of a patient’s genome in two days or less.

PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America

Retrieved on: 
Thursday, February 23, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Pancreatic serous cystadenoma, Safety, ET, Quality of life, Polycythemia, Peginterferon alfa-2a, Assistant professor, Medical Affairs Bureau, Disease, CALR, Patient, UT, Bone marrow, Mutation, Hematology, Blood, JAK2, Identity provider (SAML), Ruxolitinib, Pharmaceutical industry

ET is a rare blood cancer characterized by a genetic mutation triggering the overproduction of platelets in the blood.

Key Points: 
  • ET is a rare blood cancer characterized by a genetic mutation triggering the overproduction of platelets in the blood.
  • It is part of a group of disorders called myeloproliferative neoplasms (MPNs), for which there are few therapeutic options today.
  • Without proper treatment, ET often progresses toward myelofibrosis or secondary acute myeloid leukemia (sAML).
  • Those who respond to treatment will be eligible to participate in an extension phase of the study.

Lynda Carter Altman Helping Fund Research at City of Hope and Translational Genomics Research Institute (TGen) to Accelerate Advancements in Blood Cancer Diagnostics and Treatment

Retrieved on: 
Thursday, September 8, 2022
Research, Entertainment, Pharmaceutical, Philanthropy, Oncology, Genetics, Celebrity, Fund Raising, Foundation, Science, Biotechnology, Health, Partnership, HIV disease progression rates, Ruxolitinib, National Cancer Institute, Research, Technology, Cancer, CAR, Caligiuri, City of Hope, Identity provider (SAML), YouTube, Solution, Precision medicine, Lists of diseases, City, City of Hope National Medical Center, Infection, Â, Physician, LinkedIn, Translational Genomics Research Institute, Multimedia, Goal, Organization, Lymphatic system, Medicine, Health, Instagram, Immunotherapy, Haematopoietic system, Twitter, Biomarker, Robert, Efficiency, Diabetes, Clinical trial, Helen, Genomics, Patient, Pharmaceutical industry, Hope, Facebook

Carter Altmans gift will establish The Robert & Lynda Carter Altman Family Foundation Research Fund.

Key Points: 
  • Carter Altmans gift will establish The Robert & Lynda Carter Altman Family Foundation Research Fund.
  • For 100 years, City of Hope has provided quality cancer care, and we continue to turn hope into reality for our patients.
  • Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based nonprofit organization dedicated to conducting groundbreaking research with life-changing results.
  • TGen is part of City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.

Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology

Retrieved on: 
Monday, August 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, FDA, Woman, Myeloproliferative neoplasm, Disorder, Risk, Hematology, Interferon, Interferon alfa-2b, Legislation, JAK2, European Medicines Agency, PV, Private Securities Litigation Reform Act, Medical Affairs Bureau, ELN, Â, Disease, Bleeding, Essential thrombocythemia, Identity provider (SAML), Research, ET, Department, Blood, Cancer, MPN, Lymphatic system, Man, Patient, Quality of life, Twitter, Pancreatic serous cystadenoma, Therapy, Biotechnology, Safety, Polycythemia vera, Thrombosis, TSS, Polycythemia, Physician, University, Ruxolitinib, LinkedIn, MD Anderson Cancer Center, EMA, Future Oncology, Pharmacokinetics, Medical imaging, Pharmaceutical industry

Ropeginterferon alfa-2b-njft is a unique monopegylated, long-acting interferon that was recently approved to treat adults with polycythemia vera (PV), another type of MPN.

Key Points: 
  • Ropeginterferon alfa-2b-njft is a unique monopegylated, long-acting interferon that was recently approved to treat adults with polycythemia vera (PV), another type of MPN.
  • Given the well-established safety and efficacy profile demonstrated in prior studies, the treatment may represent a useful alternative to approved options for ET.
  • Physicians treating people with MPNs have lacked effective, durable therapeutics that are designed specifically for these cancers.
  • The global phase 3, randomized, open-label, multicenter SURPASS-ET (NCT04285086) trial is evaluating the safety, efficacy, tolerability, and pharmacokinetics of ropeginterferon alfa-2b-njft compared to anagrelide as second-line therapy in high-risk ET.